---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-027465"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2022-05-17T23:59:59+00:00"
generated_at: "2026-06-25T11:41:47.555198+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx authorizes $20M share repurchase program through May 2023

## Summary
- Board authorized repurchase of up to $20M of outstanding common stock.
- Repurchases may occur in open market or private transactions; program expires May 17, 2023 or when $20M is reached.
- Company will finance buybacks using available cash and cash equivalents.
- Board may modify, suspend, extend or terminate the program at any time.

## SEC filing metadata
- accession: 0001213900-22-027465
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2022-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390022027465/0001213900-22-027465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390022027465/ea160087-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-027465
- JSON: https://secwatch.observer/filing/0001213900-22-027465.json
- Plain text: https://secwatch.observer/filing/0001213900-22-027465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.